Table 7.

Tertiles of insulin, HOMA-IR, IGF-1 and IGFBPs in GORD controls compared with screening colonoscopy controls: multivariate analyses not adjusted for waist-to-hip ratio

Tertiles
	1	2	3	p Value (trend)*
Insulin, μIU/ml
Range	<3.8	3.8–7.27	>7.27	0.73
Cases	50	42	43
Controls	335	298	299
OR (95% CI)	1.0 (referent)	0.98 (0.62 to 1.54)	1.08 (0.69 to 1.71)
HOMA-IR
Range	<0.74	0.74–1.58	>1.58	0.78
Cases	50	42	43
Controls	335	299	298
OR (95% CI)	1.0 (referent)	0.97 (0.61 to 1.53)	1.07 (0.68 to 1.69)
IGF-1, ng/ml
Range	<94.5	94.5–130.9	>130.9	0.08
Cases	49	42	44
Controls	311	310	311
OR (95% CI)	1.0 (referent)	0.77 (0.48 to 1.22)	0.66 (0.40 to 1.05)
IGFBP-1, ng/ml
Range	<13.9	13.9–31.5	>31.5	0.57
Cases	49	42	44
Controls	319	306	308
OR (95% CI)	1.0 (referent)	0.84 (0.53 to 1.34)	0.87 (0.55 to 1.38)
IGFBP-3, ng/ml
Range	<3286	3286–4020	>4020	0.76
Cases	48	42	45
Controls	313	309	310
OR (95% CI)	1.0 (referent)	0.91 (0.56 to 1.46)	0.93 (0.58 to 1.49)
Molar ratio of IGF-1 to IGFBP-3
Range	<0.103	0.103–0.119	>0.119	0.0008
Cases	55	40	40
Controls	351	194	387
OR (95% CI)	1.0 (referent)	1.06 (0.66 to 1.69)	0.45 (0.27 to 0.72)

^*Adjusted for age, gender, race (Caucasian vs other)

BO, Barrett’s oesophagus; GORD, gastro-oesophageal reflux disease; HOMA-IR, homeostatic model for assessment of insulin resistance; IGF-1, insulin growth factor 1; IGFBP-1, IGFBP-3, IGF binding proteins 1 and 3.